Win-Win Merger Gives Celera Chem Capability, Bolsters Axys Bioinformatics | GenomeWeb

Celera Genomics took a decisive step toward its goal of becoming a fully integrated drug discovery company last week with its acquisition of Axys Pharmaceuticals in a stock transaction valued at $173.4 million.

While the Rockvile, Md.-based company has been telling investors for months that it intended to make an aggressive push toward the clinic, the merger marks the first external move Celera has taken to expand its resources beyond its core capabilities.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.